You are here

Axcella long COVID treatment helps some patients in small trial

Primary tabs

Axcella long COVID treatment helps some patients in small trial

Tue, 2022-08-02 21:49 — FNUOvviyaa

Axcella long COVID treatment helps some patients in small trial One of the first trials aimed at tackling long COVID helped some patients recover from lingering physical and mental fatigue, although the drug developed by Axcella Health Inc failed on the small study's main goal of restoring the normal function of mitochondria - the energy factories of cells. In the 41-patient pilot study released on Tuesday, for three of 21 patients who received the drug, AXA1125, their physical fatigue scores returned to normal levels after 28 days of treatment, Axcella Chief Medical Officer Margaret Koziel said in a phone interview. Others who received the drug also reported physical and mental improvements that were deemed to be statistically significant as shown on a scale developed to measure chronic fatigue, according to the preliminary results, and the drug was shown to be safe and well tolerated. YahooNews

...

Country / Region Tags:

General Topic Tags:

Medical Testing

Problem, Solution, SitRep, or ?:

Groups this Group Post belongs to:

- Private group -

Log in or register to post comments

Workflow history

Revision ID	Field name	Date	Old state	New state name	By	Comment	Operations
			No state	No state

Page loaded in 0.502 seconds.